ArticleAmerican journal of translational research2025
Diagnosis of neuromyelitis optica with bilateral vision loss as initial symptom secondary to acute middle encephalitis: a report of three cases.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuromyelitis optica (NMO) is an inflammatory demyelinating syndrome primarily characterized by optic neuritis and longitudinally extensive myelitis. However, the heterogeneity of neuromyelitis optica spectrum disorders (NMOSD) has expanded beyond the classical definition, revealing increased phenotypic diversity. Around 20-40% of NMOSD patients present with brainstem or hypothalamic involvement as their initial symptom. Case studies describing NMOSD with midbrain syndrome as the primary presentation are rare. This report details three cases where acute bilateral vision loss was the first symptom, followed by midbrain dysfunction, with a final diagnosis of NMOSD confirmed by serum AQP4 antibody testing or characteristic imaging findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.